Marjolaine Morgand1, Marc Buffet, Marc Busson, Pascale Loiseau, Sandrine Malot, Kahina Amokrane, Catherine Fortier, Jonathan London, Guy Bonmarchand, Alain Wynckel, François Provôt, Pascale Poullin, Philippe Vanhille, Claire Presne, Dominique Bordessoule, Stéphane Girault, Yahsou Delmas, Mohamed Hamidou, Christiane Mousson, Cécile Vigneau, Alexandre Lautrette, Jacques Pourrat, Lionel Galicier, Elie Azoulay, Frédéric Pène, Jean-Paul Mira, Eric Rondeau, Mario Ojeda-Uribe, Dominique Charron, Eric Maury, Bertrand Guidet, Agnès Veyradier, Ryad Tamouza, Paul Coppo. 1. Service d'Hématologie, Centre de Référence des Microangiopathies Thrombotiques, Hôpital Saint-Antoine, Université Pierre et Marie Curie, Paris, France; Service de Réanimation Polyvalente, Hôpitaux Universitaires de l'Est Parisien, AP-HP et UPMC Univ Paris 06, Paris, France; Inserm U1009, Institut Gustave Roussy, Villejuif, France; Laboratoire Jean Dausset d'Immunologie et d'Histocompatibilité & INSERM, AP-HP, UMRS 940, Paris, France; Service d'Immunopathologie, Service de Réanimation, Hôpital Saint-Louis, Université Paris 7 Denis Diderot, Paris, France; Service de Réanimation Médicale, Hôpital Charles Nicolle, Rouen, France; Service de Néphrologie, Hôpital Maison Blanche, Reims, France; Service de Néphrologie, Centre Hospitalier Universitaire, Lille, France; Service d'Hémaphérèse, Service de Médecine Interne, Hôpital de la Conception, Marseille, France; Service de Néphrologie, Centre Hospitalier de Valenciennes, Valenciennes, France; Service de Néphrologie- Médecine Interne, Hôpital Sud, Amiens, France; Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Dupuytren, Limoges, France; Service de Néphrologie, Hôpital Pellegrin, Bordeaux, France; Service Médecine Interne A, Hôpital Hôtel-Dieu, Nantes, France; Service de Néphrologie, Dijon, France; Service de Néphrologie, Hôpital Pontchaillou, Rennes, France; Service de Réanimation Médicale (7HO), Hôpital Gabriel Montpied, Clermont-Ferrand, France; Service de Néphrologie et Immunologie Clinique, CHU Rangueil, Toulouse, France; Service de Réanimation Polyvalente, AP-HP, Hôpital Cochin, Université Paris 5, Paris, France; Service de Réanimation Néphrologique, Hôpital Tenon, UPMC Université Paris 06, Paris, France; Service d'Hématologie, Hôpital Emile Muller, Mulhouse, France; Service d'Hématologie Biologique, Hôpital Antoine Béclère, AP-HP, Clamart et Université Paris-Sud 11, Le Kremlin-Bicêtre, France.
Abstract
BACKGROUND: Infectious events have been reported as major environmental triggers of thrombotic thrombocytopenic purpura (TTP). We detail here the potential association between infections and TTP. STUDY DESIGN AND METHODS: We recruited randomly and prospectively a cohort of 280 consecutive TTP patients during a 9-year period. Features of infection were systematically recorded. RESULTS: Features consistent with an infectious event were observed in 114 patients (41%) at time of TTP diagnosis. Infectious agents were documented in 34 cases and were mainly Gram-negative bacilli. At time of diagnosis infected patients more frequently had fever (p < 0.001). Infections at diagnosis did not impact prognosis and outcome. Thirty-six percent of patients experienced an infectious event during hospitalization, which resulted in more exacerbation of TTP (p = 0.02). Infections were not overrepresented during treatment in patients who received steroids and/or rituximab. Further genetic analysis of toll-like receptor (TLR)-9 functionally relevant polymorphisms revealed that TLR-9 +2848 G and TLR-9 +1174 A genotypes were more frequent in TTP patients than in controls (p = 0.04 and p = 0.026, respectively) and more particularly in patients negative for the Class II human leukocyte antigen system susceptibility allele DRB1*11 (p = 0.001 and p = 0.002, respectively). Haplotypes estimation showed that 1174A-2848G haplotype was significantly more frequent in TTP (p = 0.004), suggesting a primary role for this haplotype variation in conferring a predisposition for acquired TTP. CONCLUSION: Infections should be considered as an aggravating factor during the course of TTP. Particular polymorphisms in TLR-9 gene may represent risk factors for TTP.
BACKGROUND: Infectious events have been reported as major environmental triggers of thrombotic thrombocytopenic purpura (TTP). We detail here the potential association between infections and TTP. STUDY DESIGN AND METHODS: We recruited randomly and prospectively a cohort of 280 consecutive TTP patients during a 9-year period. Features of infection were systematically recorded. RESULTS: Features consistent with an infectious event were observed in 114 patients (41%) at time of TTP diagnosis. Infectious agents were documented in 34 cases and were mainly Gram-negative bacilli. At time of diagnosis infectedpatients more frequently had fever (p < 0.001). Infections at diagnosis did not impact prognosis and outcome. Thirty-six percent of patients experienced an infectious event during hospitalization, which resulted in more exacerbation of TTP (p = 0.02). Infections were not overrepresented during treatment in patients who received steroids and/or rituximab. Further genetic analysis of toll-like receptor (TLR)-9 functionally relevant polymorphisms revealed that TLR-9 +2848 G and TLR-9 +1174 A genotypes were more frequent in TTP patients than in controls (p = 0.04 and p = 0.026, respectively) and more particularly in patients negative for the Class II human leukocyte antigen system susceptibility allele DRB1*11 (p = 0.001 and p = 0.002, respectively). Haplotypes estimation showed that 1174A-2848G haplotype was significantly more frequent in TTP (p = 0.004), suggesting a primary role for this haplotype variation in conferring a predisposition for acquired TTP. CONCLUSION:Infections should be considered as an aggravating factor during the course of TTP. Particular polymorphisms in TLR-9 gene may represent risk factors for TTP.
Authors: Flora Peyvandi; Spero Cataland; Marie Scully; Paul Coppo; Paul Knoebl; Johanna A Kremer Hovinga; Ara Metjian; Javier de la Rubia; Katerina Pavenski; Jessica Minkue Mi Edou; Hilde De Winter; Filip Callewaert Journal: Blood Adv Date: 2021-04-27
Authors: Anton Letzer; Katja Lehmann; Christian Mess; Gesa König; Tobias Obser; Sven Peine; Sonja Schneppenheim; Ulrich Budde; Stefan W Schneider; Reinhard Schneppenheim; Maria A Brehm Journal: PLoS One Date: 2020-05-04 Impact factor: 3.240
Authors: Paul Knoebl; Spero Cataland; Flora Peyvandi; Paul Coppo; Marie Scully; Johanna A Kremer Hovinga; Ara Metjian; Javier de la Rubia; Katerina Pavenski; Jessica Minkue Mi Edou; Hilde De Winter; Filip Callewaert Journal: J Thromb Haemost Date: 2019-12-09 Impact factor: 5.824
Authors: Nicolas Beranger; Sandrine Benghezal; Bérangère S Joly; Sophie Capdenat; Adeline Delton; Alain Stepanian; Paul Coppo; Agnès Veyradier Journal: Res Pract Thromb Haemost Date: 2020-12-15